Recombinant Human MCL1 Protein, Myc/DDK-tagged, C13 and N15-labeled

• Cat.No.: MCL1-5820H
• Product Overview: MCL1 MS Standard C13 and N15-labeled recombinant protein (NP_068779) with a C-terminal MYC/DDK tag, was expressed in HEK293 cells.

Specification

• Description: This gene encodes an anti-apoptotic protein, which is a member of the Bcl-2 family. Alternative splicing results in multiple transcript variants. The longest gene product (isoform 1) enhances cell survival by inhibiting apoptosis while the alternatively spliced shorter gene products (isoform 2 and isoform 3) promote apoptosis and are death-inducing.
• Source: HEK293
• Species: Human
• Tag: Myc&DDK
• Molecular Mass: 37.2 kDa
• AA Sequence: MFGLKRNAVIGLNLYCGGAGLGAGS GGATRPGGRLLATEKEASARREIGG GEAGAVIGGSAGASPPSTLTPDSRR VARPPPIGAEVPDVTATPARLLFFA PTRRAAPLEEMEAPAADAIMSPEEE LDGYEPEPLGKRPAVLPLLELVGES GNNTSTDGSLPSTPPPAEEEEDELY RQSLEIISRYLREQATGAKDTKPMG RSGATSRKALETLRRVGDGVQRNHE TAFQGMLRKLDIKNEDDVKSLSRVM IHVFSDGVTNWGRIVTLISFGAFVA KHLKTINQESCIEPLAESITDVLVR TKRDWLVKQRGWDGFVEFFHVEDLE GGIRNVLLAFAGVAGVGAGLAYLIR TRTRPLEQKLISEEDLAANDILDYK DDDDKV
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining
• Stability: Stable for 3 months from receipt of products under proper storage and handling conditions.
• Storage: Store at -80 centigrade. Avoid repeated freeze-thaw cycles.
• Concentration: 50 μg/mL as determined by BCA
• Storage Buffer: 100 mM glycine, 25 mM Tris-HCl, pH 7.3.

Gene Information

• Gene Name: MCL1 MCL1 apoptosis regulator, BCL2 family member [ Homo sapiens (human) ]
• Official Symbol: MCL1
• Synonyms: MCL1; myeloid cell leukemia sequence 1 (BCL2-related); induced myeloid leukemia cell differentiation protein Mcl-1; BCL2L3; Mcl 1; bcl-2-like protein 3; myeloid cell leukemia ES; bcl-2-related protein EAT/mcl1; TM; EAT; MCL1L; MCL1S; Mcl-1; MCL1-ES; bcl2-L-3; mcl1/EAT; MGC1839; MGC104264
• Gene ID: 4170
• mRNA Refseq: NM_021960
• Protein Refseq: NP_068779
• MIM: 159552
• UniProt ID: Q07820

Reviews

06/20/2022

Another advantage of using MCL1 protein in trials is its potential as a therapeutic agent.

01/16/2022

The manufacturer's support and expertise further enhance the utility of MCL1 in my experimental work, ensuring reliable and high-quality results.

03/23/2016

This collaborative partnership greatly contributes to the success of my research projects and facilitates meaningful contributions to the scientific community.

Q&As

Can targeting MCL1 have implications beyond cancer therapy?

Yes, MCL1 modulation may have therapeutic implications in other diseases, such as neurodegenerative disorders, where apoptosis is a contributing factor.

Are there any diagnostic tools or biomarkers that can assess MCL1 expression in cancer patients?

Immunohistochemistry and molecular assays can be used to measure MCL1 expression levels, providing insights into the prognosis and potential treatment strategies.

How does the understanding of MCL1 function contribute to personalized medicine in cancer treatment?

Understanding MCL1 expression allows for the identification of patients who may benefit from targeted therapies, contributing to personalized treatment strategies.

Are there any ongoing clinical trials exploring MCL1 inhibitors as a therapeutic approach?

Yes, there are several clinical trials investigating the use of MCL1 inhibitors in different cancer types to assess their safety and efficacy.

How does the MCL1 protein interact with other proteins in the Bcl-2 family?

MCL1 interacts with pro-apoptotic and anti-apoptotic proteins in the Bcl-2 family, influencing the balance between cell survival and death.